Atrial Fibrillation News and Research RSS Feed - Atrial Fibrillation News and Research

Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin drug associated with higher risk of death, hospitalization among adults with atrial fibrillation

Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology. [More]
Study finds that fat around heart closely associated with atrial fibrillation

Study finds that fat around heart closely associated with atrial fibrillation

Obesity is a known risk factor for atrial fibrillation, the most common heart rhythm disorder. [More]
Findings illustrate need to monitor all races of heart failure patients for atrial fibrillation

Findings illustrate need to monitor all races of heart failure patients for atrial fibrillation

Black patients who have been diagnosed with heart failure are no less likely than white patients to get atrial fibrillation (an irregular heartbeat, or arrhythmia), according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania, which was presented today at the 2014 Scientific Sessions of the American Heart Association. [More]
Study reveals association between high burden of AFib and lower cognitive function

Study reveals association between high burden of AFib and lower cognitive function

iRhythm Technologies, Inc. announced today that study results presented during the American Heart Association Scientific Sessions showed an association between a high burden of atrial fibrillation (AFib) and lower cognitive function, specifically executive and verbal function. [More]
Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region. [More]
Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery. [More]
AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors. [More]
FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). [More]
University Medical Center's first atrial fibrillation unit opens in Germany

University Medical Center's first atrial fibrillation unit opens in Germany

Nearly 1.8 million people in Germany suffer from atrial fibrillation. This is the most common and clinically significant form of heart rhythm disorder. Shortness of breath, a sudden sense of dizziness, a feeling of pressure in the chest, and palpitations or thumping of the heart so extreme it can be felt beating rapidly and irregularly - this is how many patients describe their first episode of atrial fibrillation. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Rose Medical Center experts perform LARIAT procedure for patients with atrial fibrillation

Rose Medical Center experts perform LARIAT procedure for patients with atrial fibrillation

Rose Medical Center is now performing a groundbreaking procedure for patients with atrial fibrillation (AFib) that may reduce their risk for stroke when they cannot take blood thinners due to special circumstances. [More]
High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements, rich in omega-3 fatty acids, do not reduce atrial fibrillation, a common type of irregular heartbeat in which the heart can beat as fast as 150 beats a minute. The results of the AFFORD trial led by the Montreal Heart Institute were published in the Journal of the American College of Cardiology on October 7th. [More]
Blood test can help identify people at increased risk of atrial fibrillation, stroke

Blood test can help identify people at increased risk of atrial fibrillation, stroke

Many of those who are genetically predisposed to develop atrial fibrillation, which dramatically raises the risk of stroke, can be identified with a blood test. This is shown by new research from Lund University in Sweden. [More]

Acutus Medical concludes additional $26.2M financing round to broaden its product portfolio

Acutus Medical, Inc. (ACM), a medical device company developing a minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system to identify the sources that cause and / or sustain complex cardiac arrhythmias, including atrial fibrillation, announced it has completed an additional $26.2M financing to continue developing its imaging/mapping system as well as bring to market a complete product portfolio. [More]
Cardiac arrhythmias pose risk in pulmonary hypertension patients

Cardiac arrhythmias pose risk in pulmonary hypertension patients

Supraventricular arrhythmias are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension, a study shows. [More]

New AliveECG app provides patients with free real-time AF detection in ECG recordings

AliveCor, Inc. announced today the launch of the latest version of the AliveECG app, which provides patients with free real-time atrial fibrillation (AF) detection in ECG recordings using its new FDA-cleared algorithm. [More]
CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland of the Barostim neo System for the treatment of heart failure. [More]
Enlargement of left atrial appendage may be a risk factor of strokes with cardiac origin: Finnish study

Enlargement of left atrial appendage may be a risk factor of strokes with cardiac origin: Finnish study

More than half of the patients who have suffered a stroke with no well-defined aetiology have an enlarged left atrial appendage of the heart, according to a Finnish study. The results indicate that the enlargement of the left atrial appendage may be an independent risk factor of strokes with cardiac origin. [More]
New evidence-based guidelines for prevention, treatment of POAF

New evidence-based guidelines for prevention, treatment of POAF

The American Association for Thoracic Surgery has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation (POAF) and flutter for thoracic surgical procedures. [More]
Metabolic abnormalities predict severe hypertension

Metabolic abnormalities predict severe hypertension

Components of the metabolic syndrome, as well as a family history of hypertension, identify people at risk of developing severe hypertension, say researchers. [More]